Contents Link Navigation Link
ABOUT US

Targeting, Attacking, and Eradicating Cancers®

Company History

Targeting, Attacking, and Eradicating Cancers®

2017
Aug.Collaboration with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors
markmark
2017
July.Approval by the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer

may.Collaboration with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors
markmarkmark
2016
Dec.SillaJen is listed on KOSDAQ market in South Korea.

Jan.SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer.
markmarkmark
2015
Oct.SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products".
markmark
2015
Apr.SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer.
mark
2014
Mar.SillaJen acquires Jennerex, Inc., the global leader in oncolytic immunotherapeutics.
Jennerex was an early leader in the oncolytic virus field.Jennerex researchers showed that Pexa-Vec acts in three distinct ways to attackcancer: by infecting and killing cancer cells, by cutting off the blood supply totumors, and by activating the body’s own immune system to fight cancer.
mark
2013
May.US FDA designated Pexa-Vec as an orphan drug.
mark
2011
Jun.Jennerex initiated Pexa-Vec Phase 2b clinical trial (HEP018) for Liver Cancer.
markmark
2009
Nov.European Medicines Agency (EMA) designated Pexa-Vec as an orphan drug for Liver Cancer.
markmarkmark
2008
Aug.Jennerex initiated Pexa-Vec Phase 2a clinical trial (HEP007).
mark
2007
Aug.Jennerex completed Pexa-Vec Phase 1 clinical trial (HEP001).
markmark
2006
Mar.SillaJen, Inc. was established.
markmarkmark
2003
Nov.Jennerex, Inc. (San Francisco, USA) was established.
mark